0.7813
5.01%
0.0373
Handel nachbörslich:
.80
0.0187
+2.39%
Warum fällt Coherus Biosciences Inc-Aktie (CHRS)?
Wir haben während der Handelssitzung 2024-11-13 einen Rückgang der Aktie Coherus Biosciences Inc (CHRS) um 5.44% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!
2023-11-07:
Shares of Coherus BioSciences (CHRS) dropped by 30.23% from $3.54 to $2.47 in the trading on Tuesday, November 7, 2023. The reason why CHRS down is due to the company's mixed third-quarter financial results and lowered full-year guidance:
- Q3 Results: Coherus reported quarterly revenue of $74.6 million, indicating a 27% year-over-year growth. However, the company also posted an adjusted (non-GAAP) net loss of $26.9 million, equivalent to $0.27 per share. This net loss was wider than analyst expectations, as they had anticipated a narrower loss of $0.20 per share on revenue of $82 million.
- Guidance Update: Coherus lowered its 2023 net product revenue outlook to $250 million to $260 million from at least $275 million previously. The company also reduced its combined research and development, and sales, general, and administrative expenses guidance for 2023 to $300 million to $310 million from $315 million to $335 million. Delays in the commercial launches for Udenyca OnBody and Loqtorzi were cited as primary reasons for the revised guidance.
2023-09-25:
Coherus BioSciences, Inc. (CHRS) fell 9.19%. The company announced the FDA issued a complete response letter for UDENYCA ONBODY biologics license application solely due to an ongoing review of inspection findings at a third-party filler.
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):